entertainment -WSS

entertainment

author：knowledge 2025-09-09 19:31:27 - browse：21

A dosage of Wegovy, a drug used for weight loss — Amanda Andrade-Rhoades/AP

U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment.

The new label indicates that Wegovy can be used to reduce the risk of major heart complications — including heart attack, stroke, or cardiovascular-related deaths — for people with overweight or obesity and existing heart disease, Novo said in a statement Friday.

The decision was based on results of a large, five-year trial that showed Wegovy cut the risk of cardiovascular problems by 20% in that population. This is the first time a weight loss treatment has been approved to also help improve heart outcomes, the FDA said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Copay coupons to count toward deductibles, after Biden court move

focus

WSS

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Biotech venture capitalists face new demands from investors

The tragedy of Johnson & Johnson’s Covid vaccine

How medical schools plan to diversify without affirmative action

FDA approves updated Covid vaccines

White House touts steps to stem shortages of cancer treatments

focus

entertainment

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

FDA clears AI tool for detecting skin cancer

Jerome Adams on the need for new antivirals for Covid

Popular nasal decongestant doesn't actually relieve congestion

Walensky prepares to leave CDC — and Congress — behind

White House touts steps to stem shortages of cancer treatments

Wildfire smoke exposes gaps in outdoor worker protections

Prior authorization will have to move faster under new Biden rule

Hepatitis C has a cure — but many Americans still lack access to it

Biotech venture capitalists face new demands from investors

entertainment

Think you might have Covid

Parkinson’s finding may lead to tests and, someday, treatments

How medical schools plan to diversify without affirmative action

Long Covid needs a new name — and a new frame

Humana cuts profit projections as Medicare Advantage costs soar

Copay coupons to count toward deductibles, after Biden court move

hotspot

focus

Wikipedia

Wikipedia